Csenge Advisory Group’s Vanda Pharmaceuticals VNDA Stock Holding History

Csenge Advisory Group’s Portfolio VNDA Stock Details VNDA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-17	Closed	–	–	1447
2018 Q3	$0	Buy	+17	New	+$347	﹤0.01%	1644

Other funds holding VNDA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return

Csenge Advisory Group's VNDA Position: Q4 2018 in Review

Csenge Advisory Group sold out of Vanda Pharmaceuticals (VNDA) in Q4 2018, closing a stake of 17 shares.

Csenge Advisory Group first reported a position in VNDA in Q3 2018 and held it in 1 quarter. The position peaked at $0 in Q3 2018. 186 funds tracked by Wall St. Rank hold VNDA as of Q4 2018.

Csenge Advisory Group reported no remaining Vanda Pharmaceuticals position as of Q4 2018 after selling out during the quarter.
Csenge Advisory Group sold 17 Vanda Pharmaceuticals shares in Q4 2018.
Csenge Advisory Group first reported a position in Vanda Pharmaceuticals in Q3 2018 and held it in 1 quarter.
Csenge Advisory Group's Vanda Pharmaceuticals position peaked at $0 in Q3 2018.
186 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q4 2018.

Based on Csenge Advisory Group's 13F filing for Q4 2018, filed 7 Feb 2019.